A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples

Citation
T. Illmer et al., A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples, LEUK RES, 23(7), 1999, pp. 653-663
Citations number
37
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
LEUKEMIA RESEARCH
ISSN journal
01452126 → ACNP
Volume
23
Issue
7
Year of publication
1999
Pages
653 - 663
Database
ISI
SICI code
0145-2126(199907)23:7<653:ANPMST>2.0.ZU;2-L
Abstract
Determination of the MDR-phenotype in patients suffering from AML is an imp ortant hallmark of treatment outcome but is often complicated by technical problems in P-gp assessment. A PCR-MIMIC strategy was employed to construct PCR-fragments for a competitive and quantitative mdrl reverse transcriptio n-PCR-assay. Using K562 cells, which had been selected for drug resistance to the epipodophyllotoxin VP16, a stepwise increase of mdrl levels dependin g on the concentration of VP 16 was shown with the MIMIC technique. Compari son of mdrl levels in drug selected K562 cells with the corresponding level s for P-gp and functional data indicated a mRNA threshold that has to be ex ceeded for the full expression of the MDR-phenotype. Subsequently mdrl leve ls of 34 samples of de novo acute myeloid leukemia were determined with the PCR-MIMIC strategy. Ten patient samples could be identified with elevated mdrl levels which were substantially lower than the levels observed in the MDR-cell line K 562 0.7 mu M VP16. Outcome analysis revealed that eight of the ten patients had an unfavourable prognosis and did not achieve CR after induction chemotherapy. Coexpression of mdrl and CD 34 was not associated with CR in all examined cases. Moreover all these patients had unfavourable cytogenetic aberrations. These data indicate a sensitive technique with ap plicability in patient material. (C) 1999 Elsevier Science Ltd. All rights reserved.